A bioactive peptide analogue for myxoma virus protein with a targeted cytotoxicity for human skin cancer in vitro

Journal of Biomedical Science

Volumn 19, Issue 1, 2012, Pages

  Almansour, Nahlah M ^a   Pirogova, Elena ^a   Coloe, Peter J ^a   Cosic, Irena ^a   Istivan, Taghrid S ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

Bioactive peptide; Carcinoma; Melanoma; Myxoma virus; RRM MV

Indexed keywords

ANTINEOPLASTIC AGENT; MYXOMA VIRUS PEPTIDE ANALOGUE; PROTEIN KINASE B; UNCLASSIFIED DRUG; VIRUS PROTEIN; PEPTIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASSAY; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; ERYTHROCYTE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LIMIT OF QUANTITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE HEMOLYSIS ASSAY; SKIN CANCER; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; GENETICS; MELANOMA; METABOLISM; MYXOMA VIRUS; NECROSIS; SIGNAL TRANSDUCTION; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

MYXOMA VIRUS;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; DNA FRAGMENTATION; HUMANS; MELANOMA; MYXOMA VIRUS; NECROSIS; PEPTIDES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84864428279     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-19-65     Document Type: Article

References (41)

1. Enhancing immune responses for cancer therapy. Xue SA, Stauss HJ, Cell Mol Immunol 2007 4 173 184 17601371
2. Constitutive Activation of Akt/Protein Kinase B in Melanoma Leads to Up-Regulation of Nuclear Factor-KB and Tumor Progression. Dhawan P, Singh AB, Ellis DL, Richmond A, Cancer Res 2002 62 7335 7342 12499277 (Pubitemid 36025257)
3. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Wang G, Barrett JW, Stanford M, Werden SJ, Johnston JB, Gao X, Sun M, Cheng JQ, McFadden G, Proc Natl Acad Sci U S A 2006 103 4640 4645 10.1073/pnas.0509341103 16537421
4. Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. Barrett JW, Alston LR, Wang F, Stanford MM, Gilbert PA, Gao X, Jimenez J, Villeneuve D, Forsyth P, McFadden G, J Neurovirol 2007 13 549 560 10.1080/13550280701591526 18097886
5. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. Stanford MM, Barrett JW, Nazarian SH, Werden S, McFadden G, J Virol 2007 81 1251 1260 10.1128/JVI.01408-06 17108021 (Pubitemid 46167846)
6. Myxoma Virus Is Oncolytic for Human Pancreatic Adenocarcinoma Cells. Woo Y, Kelly K, Stanford M, Galanis C, Shin Chun Y, Fong Y, McFadden G, Ann Surg Oncol 2008 15 2329 2335 10.1245/s10434-008-9924-z 18454298
7. Myxoma Virus Is a Novel Oncolytic Virus with Significant Antitumor Activity against Experimental Human Gliomas. Lun X, Yang W, Alain T, Shi Z-Q, Muzik H, Barrett JW, McFadden G, Bell J, Hamilton MG, Senger DL, et al. Cancer Res 2005 65 9982 9990 10.1158/0008-5472.CAN-05-1201 16267023 (Pubitemid 41541479)
8. Targeting Human Medulloblastoma: Oncolytic Virotherapy with Myxoma Virus Is Enhanced by Rapamycin. Lun XQ, Zhou H, Alain T, Sun B, Wang L, Barrett JW, Stanford MM, McFadden G, Bell J, Senger DL, et al. Cancer Res 2007 67 8818 8827 10.1158/0008-5472.CAN-07-1214 17875723 (Pubitemid 47437458)
9. Oncolytic Efficacy of Recombinant Vesicular Stomatitis Virus and Myxoma Virus in Experimental Models of Rhabdoid Tumors. Wu Y, Lun X, Zhou H, Wang L, Sun B, Bell JC, Barrett JW, McFadden G, Biegel JA, Senger DL, et al. Clin Cancer Res 2008 14 1218 1227 10.1158/1078-0432.CCR-07-1330 18281557 (Pubitemid 351302571)
10. Myxoma virus and oncolytic virotherapy: A new biologic weapon in the war against cancer. Stanford MM, McFadden G, Expert Opini Biol Ther 2007 7 1415 1425 10.1517/14712598.7.9.1415 (Pubitemid 47475657)
11. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Kirn DH, Thorne SH, Nat Rev Cancer 2009 9 1 64 71 10.1038/nrc2545 19104515
12. The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Kim M, Williamson CT, Prudhomme J, Bebb DG, Riabowol K, Lee PWK, Lees-Miller SP, Mori Y, Rahman MM, McFadden G, et al. Oncogene 2010 29 3990 3996 10.1038/onc.2010.137 20473328
13. Intraventricular injection of myxoma virus results in transient expression of viral protein in mouse brain ependymal and subventricular cells. France MR, Thomas DL, Liu J, McFadden G, MacNeill AL, Roy EJ, J Gen Virol 2011 92 195 199 10.1099/vir.0.026690-0 20861319
14. M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A. Werden SJ, Barrett JW, Wang G, Stanford MM, McFadden G, J Virol 2007 81 2340 2348 10.1128/JVI.01310-06 17151107
15. AKT plays a central role in tumorigenesis. Testa JR, Bellacosa A, Proc Natl Acad Sci U S A 2001 98 10983 10985 10.1073/pnas.211430998 11572954 (Pubitemid 32928669)
16. The protein kinase B/Akt signalling pathway in human malignancy. Nicholson KM, Anderson NG, Cell Signal 2002 14 381 395 10.1016/S0898-6568(01) 00271-6 11882383 (Pubitemid 34214843)
17. Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak. Wang G, Barrett JW, Nazarian SH, Everett H, Gao X, Bleackley C, Colwill K, Moran MF, McFadden G, J Virol 2004 78 7097 7111 10.1128/JVI.78.13. 7097-7111.2004 15194786 (Pubitemid 38781548)
18. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA, Leukemia 2003 17 590 603 10.1038/sj.leu.2402824 12646949 (Pubitemid 36395654)
19. Akt as a mediator of cell death. Luo HR, Hattori H, Hossain MA, Hester L, Huang Y, Lee-Kwon W, Donowitz M, Nagata E, Snyder SH, Proc Natl Acad Sci U S A 2003 100 11712 11717 10.1073/pnas.1634990100 14504398 (Pubitemid 37206000)
20. Advances in protein kinase B signalling: AKTion on multiple fronts. Brazil DP, Yang Z-Z, Hemmings BA, Trends Biochem Sci 2004 29 233 242 10.1016/j.tibs.2004.03.006 15130559 (Pubitemid 38591317)
21. Structural characterization of the interaction between a pleckstrin homology domain and phosphatidylinositol 4,5-bisphosphate. Harlan JE, Yoon HS, Hajduk PJ, Fesik SW, Biochemistry 1995 34 9859 9864 10.1021/bi00031a006 7632686
22. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, Church D, Hassan AB, J Pathol 2005 205 145 153 10.1002/path.1712 15641016 (Pubitemid 40227987)
23. Advances in methods for therapeutic peptide discovery, design and development. Pirogova E, Istivan T, Gan E, Cosic I, Curr Pharm Biotechnol 2011 12 1117 1127 10.2174/138920111796117436 21470146
24. Macromolecular bioactivity: is it resonant interaction between macromolecules?-Theory and applications. Cosic I, IEEE Trans Biomed Eng 1994 41 1101 1114 10.1109/10.335859 7851912 (Pubitemid 24381458)
25. Virtual spectroscopy for fun and profit. Cosic I, Biotechnol 1995 13 236 238 10.1038/nbt0395-236
26. Cosic I, The Resonant Recognition Model of Macromolecular Bioactivity Birkhauser Verlag, Basel, Switzerland 1997
27. Biological effects of a de novo designed myxoma virus peptide analogue: evaluation of cytotoxicity on tumor cells. Istivan TS, Pirogova E, Gan E, Almansour NM, Coloe PJ, Cosic I, PLoS One 2011 6 24809 10.1371/journal.pone. 0024809 21949758
28. Review Study: Influence of Electromagnetic Radiation on Enzyme Activity and Effects of Synthetic Peptides on Cell Transformation. Pirogova E, Vojisavljevic V, Istivan T, Coloe PJ, Cosic I, Med Data Rev 2010 2 317 324
29. Estimating the number of viable animal cells in multi-well cultures based on their lactate dehydrogenase activities. Haslam G, Wyatt D, Kitos PA, Cytotechnology 2000 32 63 75 10.1023/A:1008121125755 19002967 (Pubitemid 30065116)
30. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Bradford MM, Anal Biochem 1976 72 248 254 10.1016/0003-2697(76)90527-3 942051
31. Characterization of a haemolytic phospholipase A2 activity in clinical isolates of Campylobacter concisus. Istivan TS, Coloe PJ, Fry BN, Ward P, Smith SC, J Med Microbiol 2004 53 483 493 10.1099/jmm.0.45554-0 15150326 (Pubitemid 38803041)
32. Bioactive peptide design using the Resonant Recognition Model. Cosic I, Pirogova E, Nonlinear Biomed Phys 2007 1 7 10.1186/1753-4631-1-7 17908333
33. Pirogova E, Istivan T, Gan E, Coloe P, Cosic I, Dössel O, Schlegel WC, Computationally Designed Interleukin-Like Peptide as a Candidate for Cancer Treatment World Congress on Medical Physics and Biomedical Engineering, September 7-12, 2009, Munich, Germany Springer, Berlin Heidelberg, Magjarevic R, 4 2009 1973 1976
34. Optimization, application, and interpretation of lactate dehydrogenase measurements in microwell determination of cell number and toxicity. Wolterbeek HT, van der Meer AJ, Assay Drug Dev Technol 2005 3 675 682 10.1089/adt.2005.3. 675 16438662 (Pubitemid 43256958)
35. Cell death: the significance of apoptosis. Wyllie AH, Kerr JF, Currie AR, Int Rev Cytol 1980 68 251 306 7014501 (Pubitemid 11219226)
36. Apoptosis. Its significance in cancer and cancer therapy. Kerr JF, Winterford CM, Harmon BV, Cancer 1994 73 2013 2026 10.1002/1097-0142(19940415) 73:8<2013::AID-CNCR2820730802>3.0.CO;2-J 8156506 (Pubitemid 24107952)
37. The Hallmarks of Cancer. Hanahan D, Weinberg RA, Cell 2000 100 1 57 70 10.1016/S0092-8674(00)81683-9 10647931 (Pubitemid 30046295)
38. Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. Cohen GM, Sun XM, Snowden RT, Dinsdale D, Skilleter DN, Biochem J 1992 286 331 334 1530564
39. The role of DNA fragmentation in apoptosis. Bortner CD, Oldenburg NBE, Cidlowski JA, Trends Cell Biol 1995 5 21 26 10.1016/S0962-8924(00)88932-1 14731429
40. Apoptosis: A Review of Programmed Cell Death. Elmore S, Toxicol Pathol 2007 35 495 516 10.1080/01926230701320337 17562483 (Pubitemid 46911891)
41. The role of cell signaling in poxvirus tropism: The case of the M-T5 host range protein of myxoma virus. Werden SJ, McFadden G, Biochim Biophys Acta 2008 1784 228 237 10.1016/j.bbapap.2007.08.001 17905673